Methodologies for the establishment of an orthotopic transplantation model of ovarian cancer in mice
Tóm tắt
This study used different methods to establish an animal model of orthotopic transplantation for ovarian cancer to provide an accurate simulation of the mechanism by which tumor occurs and develops in the human body. We implanted 4T1 breast cancer cells stably-transfected with luciferase into BALB/c mice by using three types of orthotopic transplantation methodologies: (1) cultured cells were directly injected into the mouse ovary; (2) cell suspension was initially implanted under the skin of the mouse neck; after tumor mass formed, the tumor was removed and ground into cell suspension, which was then injected into the mouse ovary; and (3) a subcutaneous tumor mass was first generated, removed, and cut into small pieces, which were directly implanted into the mouse ovary. After these models were established, in vivo luminescence imaging was performed. Results and data were compared among groups. Orthotopic transplantation model established with subcutaneous tumor piece implantation showed a better simulation of tumor development and invasion in mice. This model also displayed negligible response to artificial factors. This study successfully established an orthotopic transplantation model of ovarian cancer with high rates of tumor formation and metastasis by using subcutaneous tumor pieces. This study also provided a methodological basis for future establishment of an animal model of ovarian cancer in humans.
Tài liệu tham khảo
Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999; 17(4): 343–360
Manzotti C, Audisio RA, Pratesi G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis 1993; 11(1): 5–14
Muller WJ, Swanson I. Orthotopic and Ectopic Models of Metastasis.Experimental and Clinical Metastasis. Springer New York, 2013: 227–236
Ricci F, Broggini M, Damia G. Revisiting ovarian cancer preclinical models: implications for a better management of the disease. Cancer Treat Rev 2013; 39(6): 561–568
Hoffman RM, Yang M. Whole-body imaging with fluorescent proteins. Nat Protoc 2006; 1(3): 1429–1438
Deng XH, Sato K. Matrigel animals in the establishment of human tumor xenograft model research. Tumor (Zhong Liu) 1996; 16: 89–91 (in Chinese)
Yin AL, Zhong M, Sun GQ, Wang LP, Zhao SS. GFP-labeled human ovarian cancer orthotopic transplantation model. J South Med Univ (Nan Fang Yi Ke Da Xue Xue Bao) 2008; 28(3): 484–490 (in Chinese)
Li J, Xing H, Gao QL. Human ovarian carcinoma in nude mice model establishment and biological characteristics. Chin J Obstet Gynecol (Zhonghua Fu Chan Ke Za Zhi) 2003; 38: 376–378 (in Chinese)
Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 2003; 20(8): 745–756
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 2003; 9(1): 327–337